蹤獲弝け

Business Venture

New $30M Series B Helps Reify Health Power Clinical Trials

Illustration of doctor speaking to patient.

, which connects biopharma and research site workflows, raised a $30 million round of Series B funding to advance its cloud-based tools for the clinical trial ecosystem.

Subscribe to the 蹤獲弝け Daily

led the round, which included existing investors and . With this new round, Reify has raised just under $40 million since forming in 2012, including a $7 million Series A in 2018, co-founder and executive chairman told 蹤獲弝け News.

Boston-based Reify developed its platform, StudyTeam, four years ago to upgrade the systems health care staff at clinical research sites depend on to run trials, allowing them to reduce their workload and accelerate clinical trial enrollment.

We observed that people doing the work didnt have the software to get their job done, co-founder and CEO said in an interview. Spreadsheets, paper and sticky notes were the internal tracking system.

Some on clinical trials, but a small amount goes toward the staff working on it, Lin said. Reifys idea was to bring better tools to the front-line workers to shorten the timelines to recruiting patients while providing a consistent experience at research sites around the world, he added.

More than 1,800 research sites in 26 countries are already using Reifys product, but the new funding will help the company continue toward its goals started two years ago after the Series A round: Rolling out new features for the StudyTeam enrollment solution, product innovation and global expansion.

We see the problems day in and day out that research staff have at hospitals and clinics, and pharma wants to work with them, too, Lin said. Earlier this year, we saw the opportunity to hit the gas and sought additional investment.

In terms of growth, the company has 80 employees, and Lin expects to double that in the next 12 to 18 months. He did not disclose revenue, but said it is growing proportionately to increased adoption.

Reify Health has 10 of the top 20 pharmaceutical companies signed on as clients and is in various stages of bringing on the other 10, Passarella said. The companys next steps also include scaling the platform for better recruitment and enrollment, and adding new product functionalities.

As part of the investment, , general partner at Battery Ventures, will join Reifys board of directors, according to Lin. Agrawal said in a written statement that health care staff often have a lot of tools pushed their way, but StudyTeam has been so welcomed by clinical research sites that they are encouraging others to use it.

This results in a high level of product stickiness that creates unprecedented insights for sponsors and underlies the value of the platform to the entire ecosystem, he added.

Illustration:

Stay up to date with recent funding rounds, acquisitions, and more with the 蹤獲弝け Daily.

67.1K Followers

CTA

Discover and act on private market opportunities with predictive company intelligence.

Copy link